Acumen Pharmaceuticals, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
SCHEDULE 13D/A: RA Capital Management Updates Significant Stake in Acumen Pharmaceuticals to 24.8% Amidst Share Dilution
RA Capital Management, L.P. and its affiliates have filed an amendment to their Schedule 13D, reporting a 24.8% beneficial ownership in Acumen Pharmaceuticals, Inc., a change primarily driven by an increase in the issuer's outstanding shares rather than new transactions by the reporting group.